Section Arrow
NRIX.NASDAQ
- Nurix Therapeutics
Quotes are at least 15-min delayed:2025/07/21 16:21 EDT
After Hours
Last
 11.25
0 (0.00%)
Bid
11
Ask
11.93
High 11.25 
Low 11 
Volume 19263 
Regular Hours
Last
 11.25
+0.04 (+0.36%)
Day High 
11.7 
Prev. Close
11.21 
1-M High
14.5604 
Volume 
410.48K 
Bid
11
Ask
11.93
Day Low
11.22 
Open
11.29 
1-M Low
11.125 
Market Cap 
857.00M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 12.34 
20-SMA 12.11 
50-SMA 11.36 
52-W High 29.56 
52-W Low 8.18 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.60/-3.89
Enterprise Value
877.29M
Balance Sheet
Book Value Per Share
5.85
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
54.55M
Operating Revenue Per Share
0.90
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNFATNF Pharmaceuticals Inc.0.1294+0.0419+47.89%-- 
After Hours 0.1178 -0.0116 -8.96%
NCNANuCana plc0.051+0.0033+6.92%-- 
After Hours 0.0525 +0.0015 +2.94%
PMNProMIS Neurosciences1.12+0.6799+154.49%5PE
After Hours 1.05 -0.07 -6.25%
SABSSAB Biotherapeutics2.7+0.13+5.06%-- 
After Hours 2.65 -0.05 -1.85%
RXRXRecursion Pharmaceuticals6.4+0.56+9.59%-- 
After Hours 6.39 -0.01 -0.16%
Quotes are at least 15-min delayed:2025/07/21 16:21 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.